AACR & ASCO 2021 Midyear Review

Aumolertinib, a novel EGFR inhibitor, shows prolonged clinical benefit in a randomized comparison with gefitinib as first-line therapy in advanced non–small-cell lung cancer (NSCLC) with EGFR exon 19 del or L858R mutation. Read More ›

With 2 years’ minimum follow-up, first-line use of nivolumab, ipilimumab, and chemotherapy offers durable survival relative to chemotherapy alone in patients with advanced non–small-cell lung cancer. Read More ›

Chemotherapy plus immunotherapy (IO) may improve efficacy outcomes over IO alone in most patients with advanced non–small-cell lung cancer (NSCLC) and programmed death ligand 1 (PD-L1) scores between 1% and 49%. Read More ›

Overall survival is longer for patients with advanced non–small-cell lung cancer who received atezolizumab and had immune-related adverse events versus patients who received atezolizumab and did not have immune-related adverse events. Read More ›

Therapeutic outcomes based on plasma-based comprehensive genomic profiling are comparable to published tissue-based targeted therapy clinical outcomes in non–small-cell lung cancer (NSCLC). Read More ›

Exciting New Data Presented on NSCLC at AACR 2021
Dr David Spigel discusses key presentations on immunotherapy and targeted therapy in the neoadjuvant and adjuvant settings in NSCLC. Read More ›

Practice-Changing Data in NSCLC from ASCO 2021
Dr Mark Socinski provides his insights into important new data on EGFR inhibitors and immunotherapy in the first-line setting for NSCLC. Read More ›

Key Abstracts from ASCO 2021 in NSCLC
Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC. Read More ›

Combination Therapies and New Molecular Targets—Presentations from AACR 2021
Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents. Read More ›

After 4 years’ follow-up, nivolumab combined with ipilimumab provides durable, long-term survival benefit compared with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression. Read More ›

Page 1 of 3